Oxford Biodynamics signs agreement with Oregon University to develop Covid-19 test

Oxford Biodynamics

Oxford BioDynamics Plc, the biotech developing personalised medicine tests based on 3D genomic biomarkers, has signed a Human Material and Data Transfer Agreement with Oregon Health & Science University (OHSU) as part of its EpiSwitch™ COVID-19 disease severity test program.

Some people infected with COVID-19 become severely ill and hospitalised, while many only experience mild illness. Under the terms of the agreement, samples from OHSU will be used to further the development of the Company’s COVID-19 severity test, aimed at forecasting individuals’ risks of severe disease progression in advance, to inform risk mitigation decisions and help optimize acute and long-term treatment.

Ranked among the best hospitals in the US, OHSU has been operating right at the frontline throughout the pandemic. Since 28 February, with the first US COVID-19 hotspot on its doorstep, OHSU had seen 3,950 patient cases, as of 26 October. Clinicians have encountered and treated patients experiencing a wide range of responses, from asymptomatic through to severe cases who were admitted to intensive care or succumbed.

OHSU is the first US Academic Medical Centre to join Oxford BioDynamics’ disease severity program on a non-commercial basis as part of the COVID-19 Technology Access Framework initiative it is involved with. OHSU is providing clinical research samples from patients with the full spectrum of manifestations of COVID-19, together with in-depth expert description and annotation. These add to Oxford BioDynamics’ growing bank of 500+ samples from cohorts across the world. The Company is developing the world’s first 3D genomic test to determine likelihood of disease severity (prognostic).

Dr Jon Burrows, CEO of Oxford BioDynamics, said: “We are gratified that our disease severity program has attracted the attention and support of a prestigious institution like OHSU. We are continuing to grow our network of leading international institutions interested in analysing how the 3D genome informs COVID-19 response.”

Bill Messer, MD, PhD, Assistant Professor of Molecular Microbiology and Immunology, School of Medicine, OHSU added: “With the second wave of COVID-19 sweeping the globe, it is clear that we have a way to go in the fight against this virus.

“In April, we joined the COVID-19 Technology Access Framework, which aims to expedite the development of promising technologies to diagnose, treat and prevent COVID-19. Oxford BioDynamics shares the same mission, and their technology and its prognostic capabilities hold potential in helping both patients and the health care system.  We are glad to contribute our samples and knowledge to help advance development of the Company’s COVID-19 disease severity test.”